Kolaflavanone, a biflavonoid derived from medicinal plant Garcinia, is an inhibitor of mitotic kinesin Eg5
- PMID: 34264310
- DOI: 10.1093/jb/mvab083
Kolaflavanone, a biflavonoid derived from medicinal plant Garcinia, is an inhibitor of mitotic kinesin Eg5
Abstract
Mitotic kinesin Eg5 remains a validated target in antimitotic therapy because of its essential role in the formation and maintenance of bipolar mitotic spindles. Although numerous Eg5 inhibitors of synthetic origin are known, only a few inhibitors derived from natural products have been reported. In our study, we focused on identifying novel Eg5 inhibitors from medicinal plants, particularly Garcinia species. Herein, we report the inhibitory effect of kolaflavanone (KLF), a Garcinia biflavonoid, on the ATPase and microtubule-gliding activities of mitotic kinesin Eg5. Additionally, we showed the interaction mechanism between Eg5 and KLF via in vitro and in silico analyses. The results revealed that KLF inhibited both the basal and microtubule-activated ATPase activities of Eg5. The inhibitory mechanism is allosteric, without a direct competition with adenosine-5'-diphosphate for the nucleotide-binding site. KLF also suppressed the microtubule gliding of Eg5 in vitro. The Eg5-KLF model obtained from molecular docking showed that the biflavonoid exists within the α2/α3/L5 (α2: Lys111-Glu116 and Ile135-Asp149, α3: Asn206-Thr226; L5: Gly117-Gly134) pocket, with a binding pose comparable to known Eg5 inhibitors. Overall, our data suggest that KLF is a novel allosteric inhibitor of mitotic kinesin Eg5.
Keywords: ATPase activity; biflavonoid; kinesin Eg5; kolaflavanone; molecular interaction.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved.
Similar articles
-
Morelloflavone as a novel inhibitor of mitotic kinesin Eg5.J Biochem. 2019 Aug 1;166(2):129-137. doi: 10.1093/jb/mvz015. J Biochem. 2019. PMID: 30785183
-
In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities.Mol Cancer Ther. 2004 Sep;3(9):1079-90. Mol Cancer Ther. 2004. PMID: 15367702
-
Binding patterns of inhibitors to different pockets of kinesin Eg5.Arch Biochem Biophys. 2024 Jun;756:109998. doi: 10.1016/j.abb.2024.109998. Epub 2024 Apr 18. Arch Biochem Biophys. 2024. PMID: 38641233
-
Non-canonical functions of the mitotic kinesin Eg5.Thorac Cancer. 2018 Aug;9(8):904-910. doi: 10.1111/1759-7714.12792. Epub 2018 Jun 21. Thorac Cancer. 2018. PMID: 29927078 Free PMC article. Review.
-
Recent findings and future directions for interpolar mitotic kinesin inhibitors in cancer therapy.Future Med Chem. 2016;8(4):463-89. doi: 10.4155/fmc.16.5. Epub 2016 Mar 15. Future Med Chem. 2016. PMID: 26976726 Free PMC article. Review.
Cited by
-
Research Status and Hotspots of Anticancer Natural Products Based on the Patent Literature and Scientific Articles.Front Pharmacol. 2022 Jun 17;13:903239. doi: 10.3389/fphar.2022.903239. eCollection 2022. Front Pharmacol. 2022. PMID: 35784720 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources